PER-054-08已完成未知
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, DETERMINATION STUDY OF THE RANGE OF DOSE TO COMPARE THE SAFETY AND ACTIVITY OF MK-0518 PLUS TENOFOVIR AND LAMIVUDINE (3TC) COMPARED TO EFAVIRENZ PLUS TENOFOVIR AND LAMIVUDINE (3TC) IN PATIENTS INFECTED WITH HIV NOT SUBMITTED TO ART- EXTENSION STUDY
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2008年7月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Patients who complete the original study until Week 144 will be able to continue with this second period of study extension (the visit 14 days after therapy is not necessary in the case of patients entering the extension).
- •-All patients must provide informed consent to
- •Participate in the extension.
排除标准
- 未提供
研究者
相似试验
已完成
不适用
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, WITH DOUBLE SIMULATION, OF PARALLEL GROUPS, STUDY TO EVALUATE THE EFFECTIVENESS OF VALSARTAN 320 MG / HYDROCHLOROTHIAZIDE 12.5 MG VERSUS ENALAPRIL 20 MG / HYDROCHLOROTIZIDE 12.5 MG ON THE MEDIUM SYSTOLIC ARTERIAL PRESSURE IN POSITION SITTED IN PATIENTS WITH HYPERTENSION MODERATE-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-090-04OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, TWO-ARM PARALLEL GROUPS STUDY DESIGN TO DEMONSTRATE THE EFFICACY AND TOLERABILITY OF A SINGLE DOSE OF BDP SUSPENSION FOR NEBULISATION 1600 mcg VS PLACEBO IN THE TREATMENT OF CHILDREN AGED 6 MONTHS TO 3 YEARS WITH A CLINICAL DIAGNOSIS OF MODERATE CROUP - NDEUCTR2009-014376-22-ITCHIESI
已完成
不适用
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, CROSS-OVER DESIGN STUDY TO EVALUATE THE EFFECT OF MONTELUKAST AGAINST SALMETEROL IN THE INHIBITION OF INDUCTION OF BRONCHOCONSTRICTION INDUCED BY EXERCISES IN ASTHMATIC PATIENTS OF 6 TO 14 YEARS OF AGE-J45J45PER-058-05MERCK & CO.INC.,
进行中（未招募）
不适用
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALSALSMedDRA version: 6.1Level: PTClassification code 10002026EUCTR2005-005152-40-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO84
已完成
不适用
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 12-WEEK FACTORIAL DISTRIBUTION STUDY TO ASSESS THE EFFECTIVENESS OF SCH 58235 10 MG / DAY COADMINISTERED WITH MULTIPLE DOSES OF SIMVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA.PER-024-01SCHERING PLOUGH RESEARCH INSTITUTE,